The Effect of Preoperative Bisphosphonate Use on Total Hip Arthroplasty Outcomes
The Journal of Arthroplasty · 2023
DOI: 10.1016/j.arth.2023.05.027 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Arthroplasty, 2023. Verfasst von Suin Jeong und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Medstar Georgetown University, Washington, District of Columbia. Hauptthemen laut MEDLINE: Arthroplasty, Replacement, Hip, Osteoporosis, Bone Diseases, Metabolic. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Patients undergoing total hip arthroplasty (THA) commonly have osteoporosis for which bisphosphonates (BPs) are Food and Drug Administration (FDA)-approved for treatment. Bisphosphonate use post-THA is associated with decreased periprosthetic bone loss or revisions, and increased longevity of implants. However, evidence is lacking for preoperative bisphosphonate use in THA recipients. This study investigated the association between bisphosphonate use pre-THA and outcomes. METHODS: A retrospective review of a national administrative claims database was conducted. Among THA recipients who had a prior diagnosis of hip osteoarthritis and osteoporosis/osteopenia, the treatment group (BP-exposed) consisted of patients who had a history of bisphosphonate use at least 1 year before THA; controls (BP-naive) comprised patients who did not have preoperative bisphosphonate use. The BP-exposed were matched to BP-naive in a 1:4 ratio by age, sex, and comorbidities. Logistic regressions were used to calculate the odds ratio for intraoperative and 1-year postoperative complications. RESULTS: The BP-exposed group had significantly higher rates of intraoperative and 1-year postoperative periprosthetic fractures (odds ratio (OR): 1.39, 95% confidence interval (CI): 1.23, 1.57) and revisions (OR: 1.14, 95% CI: 1.04, 1.25) compared with the BP-naive controls. BP-exposed also experienced higher rates of aseptic loosening, dislocation, periprosthetic osteolysis, and stress fracture of the femur or hip/pelvis compared to the BP-naive controls, but these values were not statistically significant. CONCLUSION: The use of bisphosphonates in THA patients preoperatively is associated with higher rates of intraoperative and 1-year postoperative complications. These findings may impact the management of patients undergoing THA who have a prior diagnosis of osteoporosis/osteopenia and use of bisphosphonates. LEVEL OF EVIDENCE: Retrospective Cohort Study (Level 3).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Medstar Georgetown University, Washington, District of Columbia.
- Department of Orthopaedics, MedStar Union Memorial Hospital, Baltimore, Maryland.
Zitieren
APA
Jeong, S., Lee, J. W., & Boucher, H. R. (2023). The Effect of Preoperative Bisphosphonate Use on Total Hip Arthroplasty Outcomes. The Journal of Arthroplasty. https://doi.org/10.1016/j.arth.2023.05.027
Vancouver
Jeong S, Lee JW, Boucher HR. The Effect of Preoperative Bisphosphonate Use on Total Hip Arthroplasty Outcomes. The Journal of Arthroplasty. 2023. doi:10.1016/j.arth.2023.05.027
BibTeX
@article{Jeong2023,
author = {Jeong, Suin and Lee, Ji Won and Boucher, Henry R},
title = {The Effect of Preoperative Bisphosphonate Use on Total Hip Arthroplasty Outcomes},
journal = {The Journal of Arthroplasty},
year = {2023},
doi = {10.1016/j.arth.2023.05.027}
}
EUVIMED